When GLP-1 receptor agonists are used with insulin or sulfonylureas, the risk of hypoglycaemia increases, and dose reductions of these medications may be necessary
Increasing innovation in flavour and formulation variety
Recently, Semaglutide has been approved by the FDA for weight loss in obese and certain overweight patients

International AEM Malta Edward John Despott UOM Georgios Kalopitas Alberto Murino Fujifilm Healthcare Europe European Society of Gastrointestinal Endoscopy (ESGE) UEG - United European Gastroenterology American Society for Gastrointestinal Endoscopy (ASGE) Endoscopy on Air Foundation for Interventional & Therapeutic Endoscopy Erbe Group American College of Gastroenterology To view or add a comment, sign in Sphenopalatine Ganglion Radiofrequency Ablation for Craniofacial Pain: A Comprehensive Review of Anatomy, Procedural Technique, Clinical Evidence, and Interdisciplinary Implications --- --- Dr Indunil Karunarathna Uva Clinical Research Lab 2026 Uva Clinical Anaesthesia and Intensive Care ISSN 2827-7198, 2026 The sphenopalatine ganglion (SPG) DOI:10.5281/zenodo.20271746 , also known as the pterygopalatine ganglion, is a major extracranial parasympathetic hub with critical roles in trigeminal autonomic cephalalgias (TACs) and other refractory craniofacial pain syndromes

Keep your liposomal antioxidant fresh and working at its best!
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity